Division of pSivida Ltd./pSivida Inc.
Latest From pSivida Inc.
Public Company Edition: Four more IPOs in the US bring the year's total to seven – all in February. Also, Agenus launched its digital security offering, MacroGenics leads recent follow-on offerings and four companies reveal new job cuts.
Yutiq, for posterior uveitis, will compete with two existing steroid products and should launch during the first quarter of 2019. EyePoint’s Dexycu, although approved in February, is still in scale-up and probably will launch a bit later.
Public Company Edition: Is the IPO bubble getting ready to burst? It's anybody's guess, but biopharma companies are forging ahead, having launched 11 first-time offerings during the past week and a half. Also, Heron leads recent follow-on offerings with a $200m stock sale to fund what may soon be its third commercial product.
- Implantable Devices
- Controlled Release
- Site Specific
- Drug Delivery
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Control Delivery Systems Inc.
- North America
- Parent & Subsidiaries
- pSivida Ltd.
- Senior Management
Paul Ashton, PhD, Pres. & CEO
Michael J Soja, VP, CFO
Robert Shimizu, VP, Bus. Dev.
Kenneth Walters, SVP, R&D & Clinical Affairs
- Contact Info
Phone: (617) 926-5000
313 Pleasant St.
Watertown, MA 02472
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.